30.04.2019 SHOP APOTHEKE EUROPE N.V.  NL0012044747

DGAP-News: SHOP APOTHEKE EUROPE N.V.: General Meeting confirms company's European growth strategy.


 

DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): AGM/EGM
SHOP APOTHEKE EUROPE N.V.: General Meeting confirms company's European growth strategy.

30.04.2019 / 12:52
The issuer is solely responsible for the content of this announcement.


NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.

SHOP APOTHEKE EUROPE N.V.: General Meeting confirms company's European growth strategy.

  • Resolutions proposed by management accepted by large majorities.
  • Management and Supervisory Boards confirmed for another term.


Venlo, the Netherlands, 30 April 2019. Today's Annual General Meeting of SHOP APOTHEKE EUROPE N.V. confirms the growth strategy of Europe's leading online pharmacy. 54.37% of share capital, equivalent to 6,565,392 of shares were represented. The members of the Management Board reviewed the 2018 fiscal year and explained the strategy and forecast for the 2019 fiscal year to the shareholders in attendance. The General Meeting approved the resolutions put forth by management by large majorities.

The agenda of this year's General Meeting included the (re-)appointment of the members of the Management and Supervisory Boards all of whose terms were extended unanimously. "As a management team driven by an entrepreneurial spirit, we are committed to strong growth with a focus on profitability," emphasized Stefan Feltens, CEO of SHOP APOTHEKE EUROPE. "The shift from offline to online retailing is a major growth driver for us. We will continue to win new customers and further expand and solidify our market-leading position in Europe by leveraging our renowned European shop brands and our unique webshop platform."

Following a strong first quarter during which the Group increased its revenues by approximately 33% compared to the same period 2018 according to preliminary calculations, the Management Board confirmed its ambitious growth targets for the current fiscal year: "Thanks to our successful recent capital-raising measures, our finances are on solid footing and we have created the conditions to continue our strong organic growth both domestically and internationally. Revenues of one billion euros is the next mid-range milestone we want to reach," explains CFO Dr. Ulrich Wandel.

You can find more information about the General Meeting in the Investor Relations section of the corporate website https://shop-apotheke-europe.com/en/.
ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE one of the leading and fastest-growing online pharmacy in Continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its European market leadership. The product range for the whole family in the OTC, beauty and personal care products as well as prescription drugs segments is supplemented by high quality natural food and health products, low carb products and sports nutrition following the acquisition of nu3 GmbH in July 2018.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain, the Netherlands and Switzerland.

SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to over 3.8 million active customers fast and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive pharmaceutical consulting services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016 and on the SDAX since 24 September 2018.

MEDIA CONTACTS.

Trade and popular media:
Sven Schirmer
Phone: +49 221 99 53 44 31
Email: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
Email: presse@shop-apotheke.com

Investor relations:
Dr. Ulrich Wandel
Phone: +31 77 850 6117
Email: ulrich.wandel@shop-apotheke.com



30.04.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: ulrich.wandel@shop-apotheke.com
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 805441

 
End of News DGAP News Service

805441  30.04.2019 

fncls.ssp?fn=show_t_gif&application_id=805441&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019 2020e
Umsatzerlöse1 55,29 84,67 125,58 177,39 283,99 539,71 701,01 939,00
EBITDA1,2 -0,75 -2,39 -6,65 -8,84 -12,14 -15,56 -18,58 20,30
EBITDA-Marge3 -1,36 -2,82 -5,30 -4,98 -4,27 -2,88 -2,65 2,16
EBIT1,4 -1,88 -4,05 -8,82 -11,64 -19,20 -28,73 -33,45 0,00
EBIT-Marge5 -3,40 -4,78 -7,02 -6,56 -6,76 -5,32 -4,77 0,00
Jahresüberschuss1 -2,83 -5,04 -10,58 -18,45 -21,36 -33,61 -36,27 0,00
Netto-Marge6 -5,12 -5,95 -8,42 -10,40 -7,52 -6,23 -5,17 0,00
Cashflow1,7 -4,24 -3,68 -8,78 -17,21 -23,24 -23,54 -30,37 0,00
Ergebnis je Aktie8 -0,31 -0,56 -1,16 -2,03 -2,25 -2,79 -2,78 -0,70
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Shop Apotheke Europe
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2AR94 143,000 Halten 2.558,29
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,000 -92,90
KBV KCV KUV EV/EBITDA
8,55 - 3,65 -139,619
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
Hauptversammlung
0,00 0,00 0,00 30.04.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
14.05.2020 06.08.2020 05.11.2020 17.03.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-3,13% 43,48% 226,11% 265,26%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SHOP APOTHEKE EUROPE N.V.  ISIN: NL0012044747 können Sie bei DGAP abrufen

E-Commerce , A2AR94 , SAE , XETR:SAE